How much funding has AtaiBeckley Inc. raised?

AtaiBeckley Inc. has raised $285.0M in total funding, most recently a Series D round.

When was AtaiBeckley Inc. founded?

AtaiBeckley Inc. was founded in 2025.

Where is AtaiBeckley Inc. headquartered?

AtaiBeckley Inc. is headquartered in New York, New York, United States.

What industry is AtaiBeckley Inc. in?

AtaiBeckley Inc. operates in Biotech, Healthcare.

How many employees does AtaiBeckley Inc. have?

AtaiBeckley Inc. has 51-200 employees.

AtaiBeckley Inc.

IPO

Creating breakthroughs in mental health.

Public · New York, United States · Founded 2025 · $285.0M raised

Biotech

Healthcare

Headquarters: New York, New York
Employees: 51–200
Founded: 2025
Business Model: B2B

Total Funding: $285.0M
Last Round: $160.0M Series DMar 2021
Rounds: 2
Type: Public

About

AtaiBeckley Inc. is a clinical-stage biotechnology company formed in November 2025 through the merger of atai Life Sciences and Beckley Psytech, and publicly traded on Nasdaq (ATAI). The company is focused on developing rapid-acting, durable, and convenient treatments for mental health disorders where current options are severely limited, with a pipeline centered on psychedelic-derived compounds including mebufotenin (5-MeO-DMT) for treatment-resistant depression, DMT for treatment-resistant depression, and (R)-MDMA for social anxiety disorder. Headquartered in New York City and redomiciled to the United States in December 2025, AtaiBeckley combines deep expertise in psychedelic medicine, drug development, and commercialization to pursue large-scale patient impact in mental health.

Summary

AtaiBeckley Inc. is a Biotech company based in New York, United States, founded in 2025. It has raised $285.0M in total across 2 rounds, most recently a $160.0M Series D round in Mar 2021.